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Th17 cells have been described as short lived, but
this view is at odds with their capacity to trigger pro-
tracted damage to normal and transformed tissues.
We report that Th17 cells, despite displaying low
expression of CD27 and other phenotypic markers
of terminal differentiation, efficiently eradicated
tumors and caused autoimmunity, were long lived,
and maintained a core molecular signature resem-
bling early memory CD8+ cells with stem cell-like
properties. In addition, we found that Th17 cells
had high expression of Tcf7, a direct target of the
Wnt and b-catenin signaling axis, and accumulated
b-catenin, a feature observed in stem cells. In vivo,
Th17 cells gave rise to Th1-like effector cell progeny
and also self-renewed and persisted as IL-17A-
secreting cells. Multipotency was required for Th17
cell-mediated tumor eradication because effector
cells deficient in IFN-g or IL-17A had impaired
activity. Thus, Th17 cells are not always short lived
and are a less-differentiated subset capable of supe-
rior persistence and functionality.
INTRODUCTION
A key feature of adaptive immunity is the ability to generate long-
lived populations of self-renewing memory cells; however, the
evolutionary benefits of having robust anamnestic responses
are balanced against the burden and hazard of maintaining large
numbers of antigen-specific lymphocytes. Upon antigen stimu-
lation, both CD8+ and CD4+ T cells experience a stereotypical
clonal expansion followed by a contraction phase and the forma-
tion of memory (Kaech et al., 2002). Although CD8+ memory can
be retained almost indefinitely, the ability of CD4+ cells to persist972 Immunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc.is less understood and appears to be dependent upon the
conditions of initial antigenic exposure (Homann et al., 2001;
McKinstry et al., 2010; Taylor and Jenkins, 2011; Williams
et al., 2008). The relative efficiency with which different CD4+
T cell subsets enter into the memory pool is the matter of discus-
sion (MacLeod et al., 2009), and the analysis of memory forma-
tion is complicated because some polarized T helper (Th) cell
subsets are meta-stable and experience plasticity (Zygmunt
and Veldhoen, 2011).
In a recent report, Th17 cells were characterized as short-lived
effector cells with a limited capacity to persist that was attributed
to extinction of IL-17A secretion and low expression of CD27,
when compared with Th1 cells (Pepper et al., 2010). In this
elegant study, the authors analyzed endogenous Th1 and Th17
cells induced upon infection, thus allowing for in situ glimpses
at the ‘‘real’’ T cell response in a more naturalistic setting than
reports based on cells generated ex vivo (Surh and Sprent,
2010). However, the assertion that Th17 cells have a limited
survival potential seems at odds with their protective role in
antimicrobial immunity and the protracted tissue damage asso-
ciated with Th17 cell responses in autoimmune disorders such
as arthritis, multiple sclerosis, Crohn’s disease, uveitis, psori-
asis, and graft-versus-host disease (Carlson et al., 2009; May-
nard and Weaver, 2009; Sallusto and Lanzavecchia, 2009; Shi
et al., 2009). The view that Th17 cells are short lived also seems
contrary to the superior antitumor activity of adoptively trans-
ferred Th17 cells (Martin-Orozco et al., 2009b; Muranski et al.,
2008; Muranski and Restifo, 2009), in which persistence is
critical to achieving complete tumor eradication (Shen et al.,
2007; Zhou et al., 2005).
We therefore sought to study the phenotype, functional matu-
ration, and survival of Th17 cells in vivo by using a T cell receptor
(TCR) transgenic model in which CD4+ cells are specific for the
TRP-1 tissue differentiation antigen expressed by normal and
transformed melanocytes and are capable of eradicating large
established tumors (Muranski et al., 2008). Although Th17 cells
can become ‘‘Th1-like’’ (Bending et al., 2009; Lee et al., 2009;
Palmer and Weaver, 2010; Wei et al., 2009), it remains unclear
Immunity
Th17 Cells Are Long Livedwhy antitumor Th17-derived cells are more potent than their Th1
cell counterparts. In addition, the specific roles of IL-17A and
other type 17-related proinflammatory cytokines remain contro-
versial because they might either inhibit or promote early tumor
progression (Murugaiyan and Saha, 2009; Zou and Restifo,
2010).
We confirmed observations that Th17 cells resembled a termi-
nally differentiated CD8+ T cell population defined by low expres-
sion of CD62L and CD27. We observed, however, that those
Th17-derived cells critically required Th1 cell-like features for
the eradication of tumor, implying that the transferred Th17 cells
were not terminally differentiated and functioned—at least in
part—as precursors to Th1 cell-like cells. Therefore, we hypoth-
esized that a static immunophenotypic description may not be
sufficient to explain the functionality of Th17 cells in vivo, given
that late plasticity of Th17 cells might introduce an additional
layer of complexity to Th cell-mediated responses as they
mature. Th17-derived cells maintained a molecular profile
distinct from their Th1 cell-derived counterparts and were
enriched with genes associated with a less differentiated CD8+
memory subset (Wirth et al., 2010). We discovered that Th17
cells expressed a signature closely resembling the pattern
observed in stem cell-like memory (SCM) cells originally gener-
ated pharmacologically by activation of the Wnt-b-catenin
pathway in a CD8-based model (Gattinoni et al., 2009) and
recently identified in normal human peripheral blood (Gattinoni
et al., 2011). Functionally, these characteristics manifested
themselves not only as a superior ability to treat tumor and cause
autoimmune self-tissue destruction, but also by stem cell-like
properties such as an enhanced capability to survive, self-renew,
generate effector progeny, and enter the memory pool with
efficiency dramatically superior to that of Th1 cells.
RESULTS
Th17-Polarized TRP-1 Cells Efficiently Reject
Established Tumors
The conditions required for the induction of Th17 cells from naive
cells are becoming better understood (Ghoreschi et al., 2010;
Yang et al., 2011). On the basis of those advances, we generated
highly polarized populations of Th1 and Th17 TRP-1 cells. Intra-
cellular staining revealed that the majority of cells found in the
Th17-polarized cell cultures expressed IL-17A or canonical
Th17 cell-defining transcription factor RORgt (Figure 1A). A
high degree of polarization was further confirmed by quantitative
RT-PCR measurement of subset-specific transcription factors
Rorc (RORgt) and Tbx21 (T-bet) (Figure 1B) and by ELISA detec-
tion of IFN-g, IL-17A, and IL-17F after overnight peptide restim-
ulation (Figure 1C).
Judging by their phenotype, Th17 cell polarization directed
CD4+ cells toward terminal differentiation that could be expected
to impair in vivo functionality, because we found that the vast
majority of Th17 cells were CD44hi, CD62Llo, CD45RBlo, and
CD27lo, whereas Th1 cells retained less differentiated character-
istics, because they were mostly CD45RBhi and CD27hi and
retained a higher percentage of cells expressing CD62L (Fig-
ure 1D). These phenotypic differences could not be simply
explained by variations in proliferative history as indicated by
similar rapid CFSE dilution after the initial stimulation of naiveIcells under type 1 and type 17 polarizing conditions (Figure S1A
available online). When TRP-1 TCR transgenic Th17 cells were
transferred into mice bearing established subcutaneous mela-
nomas, they rapidly eradicated tumors whereas Th1-polarized
cells were less effective (p < 0.05, Figure 1E). Thus, in our model,
the differentiation state estimated by phenotype of the cells did
not correlate with responses observed in a functional assay of
tumor elimination. Moreover, the low expression of some other
phenotypic markers of senescence, such as CD25, KLRG1,
and PD-1, were not consistent with the view that Th17 cells are
more terminally differentiated (Figure S1B).
Th17-Polarized Cells Must Acquire Th1 Cell Features
In Vivo to Eradicate Tumor
The ability of Th17-polarized cells to acquire Th1 cell properties is
increasingly recognized, but the contribution of such plasticity to
the anti-tumor functionality of Th17 cells in vivo remains poorly
defined. In order to assess the function of Th17 cells in a variety
of genetically deficient mouse strains, we cloned the TRP-1
TCR into a retroviral vector (Figure S1C; Kerkar et al., 2011).
Comparable transduction efficiency was achieved in Th1 and
Th17 cells derived from wild-type (WT) mice and Th17-polarized
cells derived from Tbx21–/– and Ifng–/– mice (Figure S1D). TCR
gene-modified cells specifically recognized cognate TRP-1
peptide and secreted Th1 and Th17 cell-defining cytokines in
a pattern consistent with polarization conditions (Figure S1E).
Notably, we observed that Th17-polarized cells secreted high
concentrationsof IL-2, a feature typically associatedwith theearly
maturation stage in CD8+ memory cells (Klebanoff et al., 2006).
Uponadoptive transfer,weobserved aprofound impairment of
antitumor functionality in Ifng–/– Th17-polarized cells (p < 0.05,
Figure 1F). Similarly, the activity of Tbx21–/– Th17 cells was signif-
icantly diminished (p < 0.05) in comparison to WT Th17 TCR-
transduced cells (Figure 1G). In the same experiment, WT TCR-
transduced Th1-polarized cells were less efficient (p < 0.05)
than their Th17-polarized counterparts, recapitulating the results
observed in the TCR transgenic TRP-1 model. In conclusion, the
ability to differentiate into Th1 cell-like effectors is required for
effective eradication of tumor by Th17-polarized cells, under-
scoring the plasticity of this subset and suggesting itsmultipotent
precursor status. However, it remains unclear why T cells already
polarized to be Th1 cells were less effective in treating tumors.
Th17-Polarized Cells Evolve In Vivo into a Distinct Th1
Cell-like Subset
To understand the underlying differences between Th17-derived
and Th1-derived cells in vivo, we compared in vitro differentiated
Th1 and Th17 cells prior to transfer (day 0) and 5 and 15 days
after adoptive cell transfer by global gene expression analysis.
Analysis of in vitro generated cells showed 1,001 differentially
expressed transcripts: 602 were up and 399 were down with
aminimum fold change (FC) > 2 comparing Th17 versus Th1 cells
(Table S1). After transfer, the number of differentially expressed
transcripts rapidly declined (Figure 2A). Notably, comparing
Th17-derived cells with Th1 cells in vivo, the mRNA expression
of genes encoding Th17-related cytokines (Il17a, Il17f, Il22,
and Ccl20) decreased with time after transfer (Figure 2B),
whereas the abundance of transcripts encoding Th1 cell-
defining molecules Ifng and Tbx21 increased to amountsmmunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc. 973
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Figure 1. Th17-Polarized Cells Effectively Reject Large Tumors Despite Phenotypic Features Suggesting Terminal Differentiation, but Must
Acquire Type 1-like Features In Vivo
(A) Representative intracellular staining demonstrating production of IFN-g IL-17A, IL-17F, and Rorgt by Th1 and Th17-polarized TRP-1 cells generated in vitro
after 4 hr restimulationwith phorbol myrystate acetate (PMA) and ionomycin in the presence of brefeldin A. Resting polarized cells were used as negative controls.
(B) Expression of Tbx21 and Rorc in in vitro-polarized Th1 and Th17 cells was measured by quantitative reverse transcription polymerase chain reaction
(qRT-PCR) and expressed relative to b-actin (Actb).
(C) Secretion of indicated cytokines upon peptide stimulation was measured by ELISA. Error bars for (B) and (C) represent SEM (n = 3).
(D) Contour plots show expression of CD44 versus CD62L andCD4 versus CD45RB andCD27 on the surface of Th1 and Th17-polarized TRP-1 cells at day 7 after
stimulation.
(E) A total of 1 3 106 TRP-1 cells polarized into Th1 and Th17 cell subsets were injected into sublethally (5 Gy) irradiated C57/B6 mice bearing B16.10 tumors.
Tumor growth was measured serially and is represented as tumor area. Error bars represent SEM (n = 5–7).
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Th17 Cells Are Long Livedcomparable to Th1-derived cells. The expression of Th17-
related transcription factors Rora and Rorc (encoding for Rorgt)
also declined, but the latter remained overexpressed even at day
15 (6.36-fold versus Th1 cells). The initial in vitro differences in
expression of Sell (Cd62l) and Cd27 also disappeared
(Figure 2B).
Despite the acquisition of many Th1 cell-related features by
the transferred Th17 cells, the gene expression profiles of Th1
and Th17-derived cells recovered ex vivo remained different.
There remained 167 differentially expressed transcripts on day
5 (FC > 2, false discovery rate [FDR] < 0.05, n = 3) and 166 on
day 15 (FC > 2, FDR < 0.05, n = 2–4), and these numbers
increased to 188 and 237 respectively when cells were re-stim-
ulated in vitro for 2 hr (Figures 2A and 2C; Table S1). The highest
differentially expressed transcript found in Th1 cells on day 15
was Klrg1, which encodes a well-known marker of T cell senes-
cence (Figure 2D; Beyersdorf et al., 2007; Reiley et al., 2010).
Th1-derived cells also overexpressed inhibitorymolecules and
other markers of end-effector function, including granzymes
and multiple killer lectin-like subfamily receptors, Pdcd1, Lag3,
and Fasl in a pattern previously associatedwith terminal differen-
tiation and less effective in vivo antitumor activity (Gattinoni et al.,
2005; Grosso et al., 2007; Zhou et al., 2010) (Figure 2D). Th1-
derived cells also overexpressed Prdm1, which encodes
BLIMP1, a hallmark transcriptional repressor indicating terminal
differentiation (Rutishauser et al., 2009), and Zeb2, a gene
progressively upregulated during late differentiation inCD8+ cells
that encodes for zinc finger E-box-binding homeobox 2 (Fig-
ure 2E; Wirth et al., 2010).
Th17-polarized cells markedly upregulated the gene encoding
CCR7 that is closely associated with less differentiated memory
subsets and higher antitumor activity in CD8+ models. Interest-
ingly, Th17 cells highly overexpressed (10.38-fold on day 15)
the gene encoding death associated protein-like 1 (Dapl1).
Dapl1 was the most overexpressed gene in the early memory
cells lost during repeat stimulations of CD8+ cells recovered
ex vivo (Wirth et al., 2010). Dapl1 is active during early epithelial
differentiation (Sun et al., 2006), but its function in T cells is
unknown. Similarly, ventral anterior homebox 2 (Vax2), a gene
important in early ocular development that is a target of the
stem cell-associated sonic hedgehog signaling pathway, was
prominently overexpressed throughout the timecourse in Th17-
derived cells (Figure 2E; Kim and Lemke, 2006). Examples of
other genes differentially-regulated ex vivo on day 5 or 15 are
shown in Figure S2.
We verified our microarray results by flow cytometry (Figures
2F and 2G). We observed higher expression of KLRG1 on the
surface of surviving congenically marked Th1-derived TRP-1
cells and a higher frequency of CCR7hi cells in the Th17-derived
population. In addition, both populations had low expression of
CD62L and equal frequency of cells expressing CD27 that was
initially suppressed in Th17 cells, consistent with the microarray
data. Overall, serial measurements of gene expression indicated
that despite a dramatic transcriptional convergence with the Th1(F and G) Relative contribution of IFN-g and T-bet to the antitumor activity of TCR-e
were polarized as indicated and transduced with a retroviral vector encoding th
Recipients were treated with exogenous IL-2 and rVV TRP-1 vaccine. Error bars
least twice. See also Figure S1.
Icell subset, Th17-derived cells existed as a transcriptionally and
phenotypically distinct population. Th17-derived cells retained
expression of a core set of genes previously associated with
enhanced antitumor functionality in CD8+ T cells, suggesting
that they are less terminally differentiated than Th1-derived cells.
Th17-Derived Cells Maintain a Less Mature Molecular
Signature with Stem-Cell-like Features
To further assess the maturation stage of the surviving Th1 and
Th17 cell-derived populations in an unbiased manner, we per-
formed gene set enrichment analysis (GSEA) of our microarray
data (Subramanian et al., 2005). This method examines the
distribution of a reference gene set within the ranked list of genes
generated frommicroarray data. From a recently published anal-
ysis of CD8+ T cells stimulated once versus multiple times in vivo
(Wirth et al., 2010), we created two gene sets. The first consisted
of genes that were greater than 50% downregulated between
the first and the last round of stimulation (lost with maturation),
thus representing a signature of early (1) memory. The second
set included genes that were greater than 2-fold upregulated
as early (1) memory cells matured into late (4) memory cells
(induced with maturation) and consistent with a signature of
late (4) memory. Upon GSEA we observed a highly significant,
nonrandom distribution of genes associated with less maturity
(early memory signature) at the top of the ranked gene list
from the Th17 versus Th1 cell comparison on day 15 (NES =
1.5557741, p < 0.0001, FDR q = 0.07; Figure 3A and Figure S3A).
Out of 117 genes representing a less differentiated effector gene
set, 53 (45%) were significantly enriched in the Th17 versus Th1
list for day 15. Conversely, out of 103 genes contained in the late
memory signature set, 60 (58%) were overrepresented at the
opposite end (bottom) of the ranked gene expression list and
were therefore relatively enriched in the Th1 cell-derived popula-
tion (NES = 1.346455 p < 0.0001, FDR q = 0.15; Figure 3B and
Figure S3B). Thus, GSEA indicates that even after the Th17-
derived cells acquired Th1-like properties, they maintained
a molecular signature of a less mature population, whereas
surviving Th1-derived cells carried a molecular signature sug-
gesting terminal differentiation.
One of the genes at the top of the enrichment list for themolec-
ular signature of early memory cells was Tcf7, the gene encoding
T cell factor 1 (TCF-1) (Figures S4 and 3C). Tcf7 is a direct target
of the Wnt-b-catenin signaling axis, a pathway associated with
self-renewal of stem cells and survival of thymocytes (Gattinoni
et al., 2010; Staal and Sen, 2008). Tcf7 is expressed by undiffer-
entiated CD8+ T cells and is rapidly lost when T cells acquire an
effector phenotype (Gattinoni et al., 2009; Willinger et al., 2006).
Tcf7, and to a lesser extent the b-catenin binding partner
encoded by Lef1, were upregulated in Th17 cells in vitro on
day 0 and they remained relatively overexpressed ex vivo (Fig-
ure 3C). Differential expression of Axin2, Dab2, Igbf4, Jun,
Myc, Satb1, and Tcf4 (Figures S2 and S3) also may reflect the
activity of the Wnt-b-catenin pathway (Notani et al., 2010; Railo
et al., 2009). The expression of b-catenin (Ctnnb1) itself wasngineered Th17-polarized cells. CD4+ cells fromWT, Ifng–/–, and Tbx21–/– mice
e TRP-1 TCR. A total of 1.2 3 106 transduced cells were transferred as in (E).
represent SEM (n = 4–7). All tumor treatment experiments were reproduced at
mmunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc. 975
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Figure 2. Adoptively Transferred Th17 Cells Evolve In Vivo into a Distinct Th1-like Population
TRP-1 CD4+ T cells (Thy1.2+) were cultured under Th1 and Th17 cell conditions for 7 days. Serial gene expression profiling was performed on cells preserved on
the day of adoptive transfer (day 0) and on highly purified cells recovered on day 5 and 15 from spleens and lymph nodes of 5Gy irradiated B6.PL (Thy1.1+) animals
(two to four independent replicates/condition for days 5 and 15).
(A) Number of genes 2-fold up- or downregulated (FDR < 0.05 for days 5 and 15) between Th17- and Th1-polarized populations on indicated days is shown in their
resting state and upon 2 hr restimulation in vitro.
(B) Fold differences in expression of indicated genes as measured by microarray on indicated days; the red font indicates a fold difference < 2 on day 15.
(C) Heat map of the genes differentially expressed by Th17- and Th1-derived cells recovered ex vivo on day 15 (FC > 2, FDR < 0.05).
(D) Relative log2 expression of selected differentially expressed genes encoding phenotypic markers of terminal differentiation and end-effector function in Th17-
and Th1-derived cells recovered on day 15 after adoptive transfer.
(E) Relative log2 expression of selected differentially expressed genes correlating with in vivo functionality in Th17- and Th1-derived cells recovered at day 15.
Error bars for (D) and (E) represent SEM (n = 2–4). List of differentially expressed genes at day 0, 5, and 15 is shown in Table S1. See also Figure S2.
(F and G) Expression of CD62L, CD27, KLRG1, and CCR7 on surviving Th17- or Th1-derived cells. Persisting Thy1.2+ cells in spleens of B6.PL (Thy1.1+) mice
treated with Th17- or Th1-polarized cells were analyzed by flow cytometry on day 18 after adoptive transfer. Representative dot plots for indicated phenotypic
markers are shown. Bar graphs depict frequency of positive cells in Th1 and Th17 cell populations. Error bars represent SEM (n = 3), *p < 0.05, **p < 0.01, and
***p < 0.001.
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Th17 Cells Are Long Livednot affected by polarizing conditions (Figure 3C). However,
b-catenin is regulated at the protein level by the activity of the
Axin2-GSK3b-APC complex that mediates its degradation976 Immunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc.(Gattinoni et al., 2010). Consistent with this posttranslational
regulatory mechanism, we detected a massive accumulation of
b-catenin protein in Th17-polarized WT and TRP-1 transgenic
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Figure 3. Th17-Polarized Cells Maintain the
Core Molecular Signature of a Less Differ-
entiated T Cell Subset with Stem-Cell-like
Features
Gene sets representing molecular signatures of
early memory cells or late memory cells were
generated from data set obtained after multiple
rounds of in vivo stimulation of CD8+ T cells (Wirth
et al., 2010).
(A and B) Gene set enrichment analysis (GSEA)
enrichment plot of early memory signature set
(NES = 1.5557741, p < 0.0001, FDR q = 0.07) and
late memory signature set (NES = 1.346455 p <
0.0001, FDR q = 0.15) of the running enrichment
score (ES) and positions of gene set members on
the rank ordered list based on fold change of Th17
versus Th1 gene expression profiles obtained on
day 15 after adoptive transfer are shown. A full list
of genes contained in the early and late memory
signature sets with GSEA core enrichment heat
maps for each analysis are shown in Figures S3A
and S3B.
(C) Relative log2 expression of Tcf7, Lef1, and
b-catenin (Ctnnb1) on indicateddaysafter adoptive
cell transfer. Error bars represent SEM (n = 2–4).
(D) Presence of stable b-catenin was assessed by
immunoblotting on day 7 in purified CD4+ T cells
from WT (C57BL/6) donors (left panel) stimulated
with aCD3/aCD28 and in fresh TRP-1 cells (right
panel) peptide stimulated under Th1- and Th17-
polarizing conditions.
(E and F) WTCD4+ cells were cultured as in (D) and
harvested at indicated times, and TRP-1 CD4+
T cells were grown for 7 days. Expression of Tcf7
was measured by qRT-PCR and shown as ratio
versus b-actin (Actb). Error bars represent SEM
(n = 3), *p < 0.05, **p < 0.01, and ***p < 0.001. See
also Figures S3C and S3D.
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Th17 Cells Are Long Livedcells harvested at day 6, whereas there was very little protein de-
tected in Th1 cells (Figure 3D). Additionally, we analyzed the
kinetics of Tcf7 expression in wild-type cells polarized in vitro
under Th1 and Th17 cell conditions (Figure 3E). Notably, Tcf7
expression was higher at the end of the culture in Th17-polarized
cells than in naive cells and Th1-polarized controls. Parallel
observations were made in transgenic TRP-1 Th17 cells (Fig-
ure 3F) and in type 17-polarized CD8+ cells (Figure S3C–S3E).
Thus, Th17-derived cells had a molecular signature enriched
with genes present in a well-defined early memory CD8+ popula-
tion. Th17 cell polarization induced Tcf7 expression and an
accumulation of b-catenin, a pattern associated with self-
renewal of long-lived, stem cell-like memory CD8+ T cells that
in the setting of adoptive cell transfer display superior anti-tumor
activity (Gattinoni et al., 2009).
Th17 Cells Are Long Lived In Vivo
Analysis of the transcriptome indicated that Th17 cells resem-
bled self-renewing, long-lived memory CD8+ T cells with stem
cell-like properties. We therefore sought to assess the functional
properties of these Th17 cells by analyzing their resistance to
apoptosis and their ability to survive, expand, self-renew, and
generate more differentiated progeny. We used a 3H-thymidine
incorporation assay to measure proliferation in Th1- and Th17-
polarized cells (Figure 4A). We observed significantly lowerIthymidine incorporation in the Th1 cultures after restimulation
with anti-CD3 and anti-CD28 mAbs. Accordingly, we enumer-
ated more viable Th17-derived cells than Th1 control cells (Fig-
ure 4B). These two measures represent a complex mixture of
proliferation and activation-induced cell death (AICD). Because
CFSE-dilution experiments indicated that levels of proliferation
were similar (data not shown), we sought to assess the relative
contribution of apoptosis in the increased accumulation of cells
in the Th17-derived cell cultures. We found greater induction of
apoptosis in Th1-derived cultures as assessed by costaining
with annexin V and a nucleic acid viability stain (Figure 4C). We
also found that Th1 cells rapidly downregulated the antiapop-
totic factor Bcl2, whereas in Th17 cells the expression of Bcl2
increased after reactivation (Figure 4D). Thus, Th17-polarized
cells are resistant to AICD in vitro. These data are consistent
with the hypothesis that Th17 cells are less senescent.
We sought to apply a very stringent in vivo assessment of T cell
‘‘fitness’’ to TRP-1 TCR transgenic T cells polarized in Th1 or
Th17 cell conditions. We have previously observed that the
ability of T cells to engraft and expand after transfer into lympho-
penic hosts is severely impaired upon terminal differentiation
(Gattinoni et al., 2005; Klebanoff et al., 2005). We therefore
compared the persistence of congenically marked Th1- and
Th17-polarized cells in vivo after transfer of cells in mice that
had received 5 Gy of total body irradiation. A representativemmunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc. 977
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Figure 4. Th17-Polarized TRP-1 Cells Expand upon Secondary Stimulation In Vitro and Are Long Lived In Vivo
(A) 3H-Thymidine incorporation in restimulated Th1 and Th17 cells was measured upon overnight incubation using the equal numbers of viable cells. Error bars
represent SEM (n = 3).
(B) Absolute number of viable cells in Th1 and Th17 cultures restimulated with anti-CD3/anti-CD28 was calculated serially at indicated days and represented as
fold expansion.
(C) Annexin V expression was measured in Th1 and Th17 cells after overnight in vitro stimulation with anti-CD3 and anti-CD28 and compared to resting cells.
(D) Expression of mRNA encoding Bcl2 was measured serially by qRT-PCR after in vitro restimulation of Th1 and Th17-polarized cells. Expression relative to
b-actin (Actb) is shown. Error bars represent SEM (n = 3). Experiments (A, B, and (C) are representative andwere replicated at least twice; *p < 0.05, **p < 0.01, and
***p < 0.001.
(E) A total of 13 106 Th1 and Th17 TRP-1 cells (Thy1.2+) were adoptively transferred into sublethally (5Gy) irradiated B6.PL mice (Thy1.1+). Spleens and inguinal
lymph nodes were harvested and analyzed by flow cytometry at indicated time points for the presence of Thy1.2+Vb14+ cells. Representative contour plots
illustrate the frequency of Thy1.2+ Vb14+ cells in spleens of animals injected with Th1- and Th17-polarized TRP-1 cells at the indicated days post transfer.
(F) Mean frequency (left panels) and total number (right panels) of persisting Thy1.2+ Vb14+ cells from animals treatedwith Th1 or Th17 cells recovered at indicated
days from spleens and inguinal lymph nodes are shown. Error bars represent SEM (n = 3–6).
(G andH) Purification of in vitro polarized Th17 TRP-1 cells was performedwith IL-17A capture reagent and flow cytometric sorting of labeled cells. Dot plots show
result of FACS sorting, as compared with similarly labeled Th1 cells used as a negative control. A total of 4 3 105 Th1 and purified Th17 cells were adoptively
transferred into B6.PL mice as described in (E). Frequency of Thy1.2+CD4+Vb14 T cells was measured in blood of recipient animals at indicated time point. Error
bars represent SEM (n = 5–7), *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S4.
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Th17 Cells Are Long Livedexample for cells recovered from a spleen is shown in Figure 4E.
We found that transferred Th17 cells engrafted and expanded
more efficiently than their Th1-derived counterparts in both978 Immunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc.spleen and lymph nodes (Figure 4F). Differences in persistence
were noted as late as 5 weeks after transfer. Addition of vaccine
and exogenous IL-2 after transfer (Muranski et al., 2008;
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Figure 5. Expression Level of CD27 on Th17 Cells
Does Not Affect Their Ability to Survive and Func-
tion In Vivo
In vitro cultured Th1 and Th17 TRP-1 cells were labeled for
the expression of Thy1.2 and CD27. CD27hi and CD27lo
Th17 subsets sorted with the Th1 cell population as
a positive control. A total of 1 3 106 cells were adoptively
transferred into 5Gy irradiated B6.PL (Thy1.1) recipient
animals.
(A) Expression of CD27 is shown on Th17 cells before and
after sorting into CD27hi and CD27lo subsets.
(B) Dot plots demonstrate frequency of surviving
CD4+Thy1.2+ TRP-1 cells in spleens of recipient animals
treated with indicated cell subset at day 36 and 58 after
adoptive cell transfer.
(C) Mean frequency (upper panel) and total number (lower
panel) of CD4+Thy1.2+ cells recovered at indicated time
points from the spleens of recipient animals. Error bars
represent SEM (n = 3–4 for Th1 and Th17 CD27lo cells, n =
2–3 for Th17 CD27hi cells).
(D) Eyes from animals analyzed on day 58 in (B) and (C)
were H&E stained and examined for evidence of autoim-
munity in the cornea, iris, photoreceptors, and choroid.
Representative examples for indicated experimental
groups are shown.
(E) Degree of self-tissue destruction in eyes harvested
from indicated experimental groups on day 58 after
adoptive cell transfer was evaluated using masked auto-
immunity score as described in materials and methods.
Error bars represent SEM (n = 4-8); (* = p < 0.05, ** = p <
0.01, *** = p < 0.001).
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Th17 Cells Are Long LivedOverwijk et al., 2003) did not abrogate the survival advantage
of Th17 cells (Figure S4A and S4B). We also compared the
persistence of adoptively transferred Th1 and Th17 cells in
nonirradiated recipients and we observed significantly higher
numbers of Th17-derived cells in recipient animals (Figure S6C
and S6D).
Because an in vitro-induced Th17 cell population is not
homogenous and contains some cells not able to produce
IL-17, it seemed plausible that this small uncommitted fraction
was responsible for the profound survival difference that we
observed upon adoptive transfer. To investigate this possibility,
we used a cytokine capture technique and flow cytometry to sort
a highly purified preparation of IL-17A-secreting TRP-1 cells
(Figure 4G). We observed superior persistence after adoptive
transfer of sorted, congenically labeled Th17 cells, whereas simi-
larly treated Th1-polarized cells were detectable at significantly
lower frequencies (Figure 4H). Analogous results were obtained
with an IL-17F reporter system (Figure S4E). These results led to
a conclusion that the observed survival of Th17 cells was not due
to a mere preferential expansion of contaminating uncommitted
cells found in Th17-polarized in vitro populations.Immunity 35, 972–Taken together, our data indicate that some
Th1-derived cells survived under highly
activating lymphopenic conditions; however,
Th17 cells underwent less AICD in vitro and
exhibited superior ability to engraft, enter the
memory pool, and persist in vivo. These obser-
vations provide functional substantiation of theobserved molecular program of survival and self-renewal
displayed by Th17-polarized cells.
Expression of CD27 Does Not Correlate with Capacity
of Th17 Cells to Survive In Vivo
Diminished persistence of Th17 cells has been previously attrib-
uted to the low CD27 expression in this population (Hendriks
et al., 2000; Pepper et al., 2010). Consistent with those reports,
TRP-1 cells polarized under Th17 cell conditions demonstrated
downregulation of CD27, but a certain degree of heterogeneity
in expression of CD27 can be observed in flow cytometric anal-
ysis (Figure 1E), raising the possibility that only less-differenti-
ated cells with higher CD27 expression survive and expand
in vivo. To address this question we performed flow cytometric
sorting of Th17-polarized cells into CD27hi and CD27lo subsets
(Figure 5A). We subsequently evaluated the persistence of those
cells in comparison to Th1 counterparts in an adoptive cell trans-
fer experiment (Figures 5B and 5C). Three weeks after transfer,
we found the highest frequency and total number of transferred
cells in mice treated with Th17 CD27lo cells, whereas mice
treated with Th17 cells purified for the high expression of CD27985, December 23, 2011 ª2011 Elsevier Inc. 979
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Figure 6. IL-17A-Secreting Cells Maintain the Ability to Self-Renew
upon Transfer into a Highly Activating Environment and Contribute
to the Effective Rejection of Tumor
A total of 1 3 106 in vitro polarized Th17 and Th1 TRP-1 cells (Thy1.2+) were
adoptively transferred into sublethally irradiated (5Gy) B6.PL (Thy1.1+) mice.
On day 36 after transfer, spleens from recipient mice were harvested and
stimulated for 6 hr with TRP-1 peptide in presence of brefeldin A.
(A) Representative dot plots show intracellular IFN-g and IL-17A in Thy1.2+
cells in the indicated experimental groups.
(B) Bar graphs show mean frequency of IFN-g- and IL-17A-secreting cells
among surviving Thy1.2+ Th1- and Th17-derived cells 36 days after adoptive
transfer. Error bars represent SEM (n = 3–6).
(C) Purified CD4+ cells from C57/B6 and IL-17A/ donors were stimulated
under Th17 cell conditions and transduced with retroviral vector encoding for
TRP-1 TCR. A total of 1.2 3 106 cells were adoptively transferred into 5Gy
irradiated C57BL/6 mice. Tumor growth was measured serially. Error bars
represent SEM (n = 5–6); *p < 0.05, **p < 0.01, and ***p < 0.001.
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Th17 Cells Are Long Livedpersisted significantly less. This difference disappeared at 5 and
8weeks after adoptive cell transfer. At every time point analyzed,
Th1-polarized cells were found at significantly lower numbers
(p < 0.05 versus Th17 CD27lo subset).
Persistence of CD27hi and CD27lo subsets of Th17-polarized
TRP-1 cells was associated with an autoimmune-like syndrome
manifested by progressive damage of melanocytes. Recipient
mice treated with Th17 cells developed extensive diffuse vitiligo
(data not shown). We have previously demonstrated a close
correlation between the degree of ocular autoimmunity and effi-
cacy of antitumor responses mediated by CD8+ Pmel1 cells
(Palmer et al., 2008). Therefore we systematically analyzed the
degree of eye damage in recipient animals on day 58 after
transfer (Figures 5D and 5E). We observed only evidence of
mild, resolved irydocyclitis and choroiditis in mice treated with
Th1-polarized cells. Animals treated with Th17 CD27hi cells
developed much more pronounced damage of pigmented
epithelium in the eyes, as manifested by moderate irydocyclitis,
significant edema, inflammatory infiltration of the choroid,
retinal folding, and cataract formation. Strikingly, the changes
observed in the group treated with Th17 CD27lo cells were
the most severe, resulting in complete disruption of eye struc-
ture, large areas of retinal degeneration, corneal neovasculari-
zation, and formation of synechiae (adhesions between iris
and cornea) with obliteration of the anterior chamber of the
eyes (Figures 5D and 5E).
Our findings thus prompt a re-evaluation of the view that
Th17 cells are short lived and destined to die because of
the low expression of CD27. In contrast, it appears that the
level of CD27 expression observed in the initial Th17 polarized
population does not affect the long term viability of Th17-
derived cells following adoptive cell transfer in vivo. Moreover,
even the Th17-derived cells with the lowest levels of this
costimulatory receptor are capable of expansion and survival
in significant numbers in vivo. In addition, Th17 cells were
capable of mediating dramatic autoimmune self-tissue
destruction.
IL-17A-Secreting Cells Are Capable of Self-Renewal
In Vivo and Contribute to Tumor Rejection
The development of Th1 cell-like progeny from Th17-polarized
cell precursors was evidenced by the critical importance of
Th1 cell-related factors for the in vivo antitumor effect of TRP-1
cells (Figures 1F and 1G). However, the importance of continued
capacity to produce IL-17A remained unclear. We found that
Th1-derived cells did not give rise to IL-17A-producing cells
when they were measured by intracellular cytokine analysis
5 weeks after adoptive transfer (Figures 6A and 6B). By sharp
contrast, highly polarized Th17 cells acquired the ability to
secrete IFN-g. However, some cells also retained the ability to
produce the Th17-defining cytokine IL-17A (Figures 6A and
6B). We therefore ascertained the role of IL17A in tumor rejection
by adoptively transferring TCR-transduced Il17a–/– Th17-
polarized CD4+ cells into tumor-bearing mice. We found
that they were significantly less effective in mediating elimination
of the tumor than wild-type derived Th17-polarized effectors
(p < 0.05, Figure 6C) suggesting that IL-17A secretion by Th17-
derived cells was also contributed to tumor rejection. These
observations indicated that Th17 cells were both self-renewing980 Immunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc.(i.e., capable of IL-17A secretion) and had the multipotent
capacity to generate progeny producing IFN-g and that both
qualities contributed to tumor treatment.
Immunity
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In this report, we investigated the anticancer responses medi-
ated by Th17-polarized cells that effectively eradicated estab-
lished tumors. The acquisition of type 1 effector properties,
including T-bet expression and the secretion of IFN-g in vivo,
was required for the antitumor activity of highly-polarized Th17
cells. Plasticity of Th17 cells in vivo has been previously
described (Lee et al., 2009; Martin-Orozco et al., 2009a; Wei
et al., 2009; Yang et al., 2009), but plasticity alone seemed insuf-
ficient to explain why Th17-polarized CD4+ T cells demonstrated
enhanced eradication of established tumors when compared
with their Th1 counterparts that already express large amounts
of T-bet and IFN-g. Although IL-17A contributes to the antitumor
function of Th17-derived cells in our model, possibly via recruit-
ment of other arms of the immune system (Martin-Orozco et al.,
2009b), the expression of IL-17A does not explain this conun-
drum, because unlike the case of genetic disruption of IFN-g
expression, elimination of IL17A only partially diminished
treatment.
The superior functionality of Th17 cells in mediating tumor
rejection and autoimmunity was associated with enhanced
survival of Th17-derived cells upon adoptive transfer. IFN-g-
producing Th1 cells have been previously reported as terminal
effectors prone to apoptosis (Wu et al., 2002), whereas Th17 cells
engraftedbetter andweremore resistant to apoptosis (McKinstry
et al., 2010; Shi et al., 2009). A hypothetical explanation for this
survival advantage was provided by Waddington who more
than 50 years ago theorized that cellular differentiation was due
to epigenetic changes that he analogized to a ball rolling downhill
(Waddington, 1957). More recently, the epigenetic control of Th
cell subset plasticity was analogized to a dissipation of biochem-
ical or physical energy and the accumulation of entropy,
a process that in a closed system efficiently proceeds only in
one direction (Murphy and Stockinger, 2010; Wei et al., 2009).
This metaphor can also be applied to the progressive maturation
ofCD8+ T cells, given that their antitumor efficacy inversely corre-
lates with advanced maturational state through limitation of their
capacity to self-renew and survive in vivo (Gattinoni et al., 2005;
Zhou et al., 2005). Terminally differentiated, end-effector CD8+
cells had the greatest ability to release IFN-g and to lyse targets
in vitro, but paradoxically exhibited limited or no antitumor func-
tion in vivo (Gattinoni et al., 2006). Conversely, less differentiated
CD8+ and CD4+ populations, including naive, central memory
(CM), and more recently stem cell-like memory (SCM) cells,
were able to efficiently survive and eradicate tumor upon adop-
tive transfer (Berger et al., 2008; Gattinoni et al., 2009; Klebanoff
et al., 2005; Xie et al., 2010).
One perplexing observation is that Th17 cell polarization
induces a phenotype that resembles end effector memory cells
(CD62LloCD27lo). CD27 is known to play a crucial role in the
survival of memory CD8+ T cells (Hendriks et al., 2000). Pepper
et al. (2010) explored the fate of endogenously generated Th
cell subsets during an infection in normal hosts. However, the
generation of Th1 or Th17 cells in vivo required incommensurate
methods of immunization that varied by route (intravenous
versus intranasal, respectively) and magnitude of response,
relying on pMHC tetramers to track the antigen-specific cells,
that interpreted the extinction of IL-17A production as evidenceIfor a limited lifespan of Th17 cells. The possibility that some Th17
cells simply experienced plasticity and lost the capacity to
produce IL-17A was discounted by the authors because the
IL-17A-secreting cells expressed low CD27 and thus were
thought to not have been able to enter into the memory T cell
pool. To support this claim, they showed that 80% of nonpolar-
ized, open-repertoire, CD27lo CD4+ cells disappeared within
14 days after the adoptive transfer, but Th17-polarized cells
were not explicitly evaluated in this context (Pepper et al.,
2010). Thus, Pepper, et al. assumed the equivalency between
CD27lo cells and Th17 polarized cells and their conclusions
were further limited by the expectation of a static regulation of
CD27 expression in every Th cell subset. In our system, we
observed excellent persistence of the congenically-marked
Th17 subset purified for the expression of even the lowest levels
of CD27, thus excluding the possibility that CD27hi cells found in
phenotypically heterogeneous in vitro cultures enjoyed a selec-
tive survival advantage. Moreover, purified CD27lo Th17 polar-
ized TRP-1 cells induced the most aggressive autoimmune-like
syndrome resulting in almost complete elimination of ocular
melanocytes and severe disruption of eye architecture, while
CD27hi Th17 cells were slightly less effective.
The apparently discrepant conclusions from data presented in
our manuscript and findings observed by Pepper, et al. mainly
represent differences of interpretation. Nevertheless, there are
important dissimilarities in experimental design. In vitro-cultured
cells used in our work probably differ from cells arising in vivo
after the resolution of acute infection (Stockinger et al., 2011;
Wahren-Herlenius and Kuchroo, 2011). Endogenous Th17 cells
and their offspring are difficult to trace, but the recently pub-
lished fate-mapping system linked to the IL-17A promoter could
potentially advance this knowledge (Hirota et al., 2011). We
transferred cells into transiently lymphopenic, sublethaly irradi-
ated but otherwise immunocompetent animals. This state was
designed to mimic clinical conditions of host lymphopenia,
including those observed in cancer patients treated with chemo-
therapy and radiotherapy (Muranski et al., 2006), but this
lymphopenia was likely to accelerate the differentiation of
Th17-polarized TRP-1 cells into the Th1 cell phenotype. At its
essence, our findings are that Th17 cells represent an ‘‘earlier,’’
less-differentiated, plastic, and more stem cell-like state than
Th1 cells. These findings have been confirmed recently by
a description of prosurvival molecular features in human Th17
cells and associated with expression of hypoxia-inducible factor
1 (HIF1a) (Kryczek et al., 2011), amolecule regulating Th17 differ-
entiation and linked to stem cell-like behavior (Dang et al., 2011;
Shi et al., 2011). Taken together, these data indicate that Th17
cells are long-lived cells capable of maturational plasticity.
The fairly simple associations between phenotypic features
(CM versus EM) and in vivo efficacy is applicable in many situa-
tions, but the core maturational program responsible for the fate
of short- or long-lived effector cells might be more important
(Haining et al., 2008). Ex vivo measurements of gene expression
profiles demonstrated that Th17-derived cells remained clearly
distinct from their Th1 counterparts, despite their evolution into
a Th1 cell-like cellular population, albeit with lower expression
of Tbx21. We used a systems biology approach to characterize
this persistent difference (Benoist et al., 2006; Haining and
Wherry, 2010). GSEA showed that Th17-derived cells retainedmmunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc. 981
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stage of CD8+ memory development, whereas the Th1-derived
population displayed features associated with late effectors.
GSEA was performed in an unsupervised manner taking into
consideration the global pattern of gene expression rather than
merely relying on the predefined expression level selection
criteria (Subramanian et al., 2005). We used a well-characterized
gene set that reflected the signatures of more or less differenti-
ated memory CD8+ cells generated in vivo (Wirth et al., 2010).
Recent work by Pepper et al. and other groups indicated that
high expression of T-bet in Th1 cells has been associated with
terminal differentiation and limited survival, whereas T-betlo
CD4+ T cells formed stable long-lived CM population, consistent
with our findings (Ballesteros-Tato and Randall, 2011; Joshi
et al., 2007; Marshall et al., 2011; Pepper et al., 2011). Thus,
a core transcriptional program might be shared between polar-
ized Th cell subsets and defined subsets of CD8+ Tmemory cells
in progressive maturational states.
Because of the self-renewal capabilities displayed by long-
lived memory T cells, analogies between stem cells and T cells
have been postulated; this notion has been recently reinforced
by descriptions of stemness-associated biological pathways
including Wnt-b-catenin in peripheral lymphocytes (Luckey
et al., 2006; Stemberger et al., 2009). We found that Th17 polar-
ization was associated with accumulation of b-catenin and
expression of Tcf7, factors that are important in themaintenance
of self-renewal in stem cells and cancer cells (Roose et al., 1999;
Staal et al., 2008). Tcf-1-b-catenin signaling is active in earlier
T cell subsets (naive, SCM, and CM cells) with high self-renewal
potential and antitumor activity (Gattinoni et al., 2009; Willinger
et al., 2006) and is associated with preservation of long-term
CD8+ and CD4+ T cell memory (Gattinoni et al., 2010; Williams
et al., 2008; Ding et al., 2008). Tcf7 inhibits production of effector
cytokines (Yu et al., 2011; Yu et al., 2009). T-bet directly
represses Tcf7 gene in Th1 cells (Oestreich et al., 2011), whereas
STAT3 signaling, critical for Th17 cell polarization, also influ-
ences survival of T cells as well as self-renewal capacity of
stem cells and cancer growth and directly regulates Tcf7 (Durant
et al., 2010; Hirano et al., 2000). The physiological relevance of
this conserved and dynamically regulated self-renewal pathway
in Th17 cells remains unclear, but multiple lines of evidence
suggest that the activity of Tcf7 can be used as an indicator of
early maturational stage and a predictor of T cell survival capa-
bility (Gattinoni et al., 2010).
In conclusion, cytokine signals received by CD4+ T cells during
priming can launch them toward a fate of programmed senes-
cence or long-term self-renewal, sustained survival, and
enhanced activity during the secondary response. Th17 cell
polarization diverted cells frompremature terminal differentiation
and generated a population with stem cell-like features of self-
renewal and enhanced ability to enter the memory pool. In
addition, Th17 cells gave rise to Th1 effector progeny in vivo,
a process that was functionally prerequisite to effectively elimi-
nate tumors, indicating multipotency. Our findings provide
potential insight into the role of these cells in autoimmune disor-
ders (Carlson et al., 2009; Palmer andWeaver, 2010) and chronic
infections, including HIV, in which depletion of mucosal IL-17A-
secreting cells has been reported (Brenchley et al., 2008). Finally,
our observations offer a mechanistic basis for the antitumor982 Immunity 35, 972–985, December 23, 2011 ª2011 Elsevier Inc.efficacy of Th17 cells in a highly realistic and clinically relevant
animal model of advanced cancer, and thus they have implica-
tions for the design of future T cell-based immunotherapy.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
BwRag1–/–TRP-1 and Pmel1 TCR transgenic mice were previously described
and bred at the National Cancer Institute, NIH animal facility (Muranski et al.,
2008; Overwijk et al., 2003). For description of all mice and cell lines used refer
to Supplemental Experimental Procedures.
Adoptive Cell Transfer Protocol
Tumor treatment experiments with TRP-1 cells were described previously
(Muranski et al., 2008). For a detailed description, see Supplemental Experi-
mental Procedures.
Retroviral Production and Transduction
Polarized CD4+ T cells from indicated donors were transduced with retroviral
vector encoding TRP-1 TCR. For a detailed description, refer to Supplemental
Experimental Procedures.
Microarray Methods
Gene expression levels were determined with GeneChip Mouse Gene 1.0 ST
arrays according to manufacturer’s protocols (Affymetrix). Description of
methods and statistical analysis is included in Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE26030.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
(including in vitro polarization and stimulation, flow cytometry, antibodies,
cytokine release assays, proliferation assays, immunoblot analysis and quan-
titative gene expression analysis by RT-PCR, and statistical methods), four
figures, and one table and can be found with this article online at doi:10.
1016/j.immuni.2011.09.019.
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